Breaking News Instant updates and real-time market news.

ATRC

AtriCure

$28.19

0.21 (0.75%)

20:18
04/25/19
04/25
20:18
04/25/19
20:18

AtriCure growth story 'underappreciated', says Piper Jaffray

Piper Jaffray analyst Matt O'Brien keeps his Overweight rating and $37 price target on AtriCure after its better than expected Q1 results and raised FY19 revenue outlook at the low end of its prior range. The analyst notes that in spite of the "very strong" appendage management trends, the company's domestic MIS has been "lumpy", which justifies the management's "conservative" outlook. O'Brien adds that while there was no update on Converge data, he sees "progress to a potential panel next year" remaining on track and believes that the company's "accelerating growth story is still underappreciated."

  • 25

    Apr

  • 08

    May

  • 22

    May

ATRC AtriCure
$28.19

0.21 (0.75%)

03/25/19
PIPR
03/25/19
NO CHANGE
PIPR
Piper sees six 'quality' Med Tech names whose stocks haven't rallied
Medical Technology stocks have rebounded quickly in Q1 following a challenging Q4 of 2018 as the combination of solid year-end results and compelling outlooks for next year have led investors back into the names, Piper Jaffray analyst Matt O'Brien tells investors in a research note. The analyst, however, has identified six "quality" names that have not participated in the Q1 share appreciation, "despite consistently delivering beat-and-raises." The basket of stocks include Abiomed (ABMD), Merit Medical (MMSI), AtriCure (ATRC), Neuronetics (STIM), SeaSpine (SPNE) and Nuvectra (NVTR).
04/02/19
BTIG
04/02/19
UPGRADE
BTIG
Buy
AtriCure upgraded to Buy from Neutral at BTIG
04/02/19
BTIG
04/02/19
UPGRADE
Target $35
BTIG
Buy
AtriCure upgraded to Buy from Neutral at BTIG
BTIG analyst Sean Lavin upgraded AtriCure to Buy from Neutral with a $35 price target following the recent share slide, telling investors in a research note that its valuation warrants a second look. Lavin says that at the current valuation, he believes investors can be rewarded through quarterly beats and "enthusiasm" ahead of Converge data and notes that fundamentals have improved as the open business has stabilized.
04/12/19
JPMS
04/12/19
INITIATION
Target $37
JPMS
Overweight
AtriCure initiated with an Overweight at JPMorgan
JPMorgan analyst Robbie Marcus started AtriCure with an Overweight rating and $37 price target. Surgical atrial fibrillation ablation represents a "large and unpenetrated market," Marcus tells investors in a research note. AtriCure is the only pure-play company focused on the surgical atrial fibrillation opportunity and faces minimal competition, adds the analyst. He points out the company offers the only product on-label to treat atrial fibrillation during open cardiac surgeries with its Isolator Synergy device.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.